![Briggs Morrison](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Briggs Morrison
Presidente presso
ARVINAS, INC.
Patrimonio netto: 1 M $ in data 30/06/2026
Profilo
Dr. Briggs W.
Morrison, MD, is an Independent Director at CRISPR Therapeutics AG, a President, Chief Executive Officer & Director at Crossbow Therapeutics, Inc., a Chairman at Arvinas, Inc., an Entrepreneur Partner at MPM BioImpact LLC and an Independent Chairman at Auron Therapeutics, Inc. He is on the Board of Directors at CRISPR Therapeutics AG, Crossbow Therapeutics, Inc., CTx Operations, Inc., Werewolf Therapeutics, Inc., ImmunoMet Therapeutics, Inc., Alliance for Clinical Research Excellence & Safety, Arvinas Operations, Inc. and Photys Therapeutics, Inc. Dr. Morrison was previously employed as an Independent Director by Carisma Therapeutics, Inc., an Independent Director by NextCure, Inc., an Independent Director by Repare Therapeutics, Inc., an Independent Director by Oncorus, Inc., a Chairman by Transcelerate Biopharma, Inc., a Chief Medical Officer by AstraZeneca PLC, a Head-Medical Affairs, Safety & Regulatory Affairs by Pfizer Inc., and a Vice President-Clinical Sciences by Merck Research Laboratories Massachusetts LLC.
He also served on the board at Codiak BioSciences, Inc., BioSight Ltd., Syndax Pharmaceuticals, Inc., Redona Therapeutics, Inc., Reunion Neuroscience, Inc. and RIFT biotherapeutics, Inc. He received his undergraduate degree from Georgetown University and a doctorate degree from The University of Connecticut School of Medicine.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
ARVINAS, INC. 0,17% | 24/06/2026 | 111.548 ( 0,17% ) | 926 964 $ | 30/06/2026 |
| 05/06/2026 | 5.209 ( 0,01% ) | 284 099 $ | 30/06/2026 | |
| 12/06/2025 | 15.523 ( 0,03% ) | 5 588 $ | 30/06/2026 | |
| 31/05/2025 | 12.175 ( 0,03% ) | 73 $ | 30/06/2026 |
Posizioni attive di Briggs Morrison
| Società | Posizione | Inizio |
|---|---|---|
| ARVINAS, INC. | Presidente | 12/02/2026 |
| WEREWOLF THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 01/11/2019 |
| CRISPR THERAPEUTICS AG | Direttore/Membro del Consiglio | 30/05/2025 |
Crossbow Therapeutics, Inc.
 Crossbow Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops antibodies for cancer treatment | Amministratore Delegato | 01/02/2022 |
Auron Therapeutics, Inc.
 Auron Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company which cure cancer by radically changing the paradigm of cancer therapeutics from cell killing to transformation of malignant cells into more normal functioning cells | Presidente | - |
Photys Therapeutics, Inc.
 Photys Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Develops proprietary bifunctional molecule therapeutics | Direttore/Membro del Consiglio | - |
CTx Operations, Inc.
 CTx Operations, Inc. BiotechnologyHealth Technology Develops macrophage-based immunotherapeutic for treatment of cancer | Direttore/Membro del Consiglio | 01/07/2020 |
Arvinas Operations, Inc.
 Arvinas Operations, Inc. BiotechnologyHealth Technology Develops protein degradation therapeutics for cancer and other diseases | Direttore/Membro del Consiglio | - |
ImmunoMet Therapeutics, Inc.
 ImmunoMet Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops drugs for the treatment of cancer | Direttore/Membro del Consiglio | 28/11/2017 |
| ░░░░░░░░ ░░░ ░░░░░░░░ ░░░░░░░░ ░░░░░░░░░░ ░░░░░ ░░░░░░ | ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ | - |
| ░░░ ░░░░░░░░░ ░░░ | ░░░░░░░░░░░ ░░ ░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Precedenti posizioni note di Briggs Morrison
| Società | Posizione | Fine |
|---|---|---|
| ░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
Formazione di Briggs Morrison
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
83
Relazioni di 1° grado
27
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 27 |
|---|---|
Pfizer Inc.
 Pfizer Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products & ingredients | Health Technology |
AstraZeneca PLC
 AstraZeneca PLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Syndax Pharmaceuticals, Inc.
 Syndax Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company | Health Technology |
Arvinas Operations, Inc.
Arvinas Operations, Inc. BiotechnologyHealth Technology Develops protein degradation therapeutics for cancer and other diseases | Health Technology |
MPM BioImpact LLC
 MPM BioImpact LLC Investment ManagersFinance MPM Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of biotechnology, healthcare and life science sectors. It participates in early stage capital transactions. | Finance |
Georgetown University
 Georgetown University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Merck Research Laboratories Massachusetts LLC
 Merck Research Laboratories Massachusetts LLC Pharmaceuticals: MajorHealth Technology Discovers, develops, and markets a broad range of human and animal health products | Health Technology |
BioSight Ltd.
 BioSight Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biotech pharmaceutical company that provides cancer drug development services | Health Technology |
The University of Connecticut School of Medicine
 The University of Connecticut School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Transcelerate Biopharma, Inc.
 Transcelerate Biopharma, Inc. BiotechnologyHealth Technology Provides biopharmaceutical research services | Health Technology |
CRISPR Therapeutics AG
 CRISPR Therapeutics AG BiotechnologyHealth Technology Develops gene-based medicines | Health Technology |
Arvinas, Inc.
 Arvinas, Inc. BiotechnologyHealth Technology Engages in discovery, development and commercialization of therapies to degrade disease-causing proteins | Health Technology |
Codiak BioSciences, Inc.
 Codiak BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops exosome based therapeutics | Health Technology |
NextCure, Inc.
 NextCure, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which discovers and develops novel immuno medicines to treat cancer & immune related diseases | Health Technology |
ImmunoMet Therapeutics, Inc.
ImmunoMet Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops drugs for the treatment of cancer | Health Technology |
Oncorus, Inc.
 Oncorus, Inc. BiotechnologyHealth Technology Operates as biotechnology company that develops next generation immunotherapy platform to treat cancer | Health Technology |
Alliance for Clinical Research Excellence & Safety
 Alliance for Clinical Research Excellence & Safety Miscellaneous Commercial ServicesCommercial Services Operates as a non-governmental organization which builds, implements and maintains comprehensive global systems | Commercial Services |
RIFT biotherapeutics, Inc.
 RIFT biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Develops antibodies for use in oncology | Commercial Services |
CTx Operations, Inc.
CTx Operations, Inc. BiotechnologyHealth Technology Develops macrophage-based immunotherapeutic for treatment of cancer | Health Technology |
Repare Therapeutics, Inc.
 Repare Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery and development of novel cancer therapies | Health Technology |
Auron Therapeutics, Inc.
Auron Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company which cure cancer by radically changing the paradigm of cancer therapeutics from cell killing to transformation of malignant cells into more normal functioning cells | Commercial Services |
Redona Therapeutics, Inc.
 Redona Therapeutics, Inc. BiotechnologyHealth Technology Develops novel therapeutics for cancer and autoimmune diseases | Health Technology |
Werewolf Therapeutics, Inc.
 Werewolf Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures medicines for cancer | Health Technology |
Photys Therapeutics, Inc.
Photys Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Develops proprietary bifunctional molecule therapeutics | Commercial Services |
Crossbow Therapeutics, Inc.
Crossbow Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops antibodies for cancer treatment | Health Technology |
Reunion Neuroscience, Inc.
 Reunion Neuroscience, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops FDA-approved serotonergic psychedelic therapeutic solutions for underserved mental health disorders | Health Technology |
Carisma Therapeutics, Inc.
 Carisma Therapeutics, Inc. BiotechnologyHealth Technology Develops novel chimeric antigen receptor macrophage and CAR-monocyte technology treatment of non-muscle invasive bladder cancer | Health Technology |
